{
    "clinical_study": {
        "@rank": "129357", 
        "arm_group": {
            "arm_group_label": "Fixed Sequence Crossover Arm", 
            "arm_group_type": "Other", 
            "description": "This study arm consists of a fixed sequence crossover where study subjects will receive Treatment A and following a washout of no less than 10 days will then receive Treatment B. The drug class is a CDK4/6 inhibitor."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine approximately what percentage of an orally\n      administered dose of PD-0332991 is absorbed from the gastrointestinal tract into the\n      systemic circulation. This approximation is made by comparing the plasma pharmacokinetics of\n      a 125 mg oral dose of PD-0332991 to the plasma pharmacokinetics of a 50 mg  intravenous dose\n      of PD-0332991 administered as a 4-hour infusion."
        }, 
        "brief_title": "A Study Comparing the Plasma Drug Exposure of an Oral Dose of Palbociclib (PD-0332991) to an Intravenous Dose of Palbociclib (PD-0332991)", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy male or female of non-childbearing potential between the ages of 18 and 55\n             years of age.\n\n          2. A body mass index (BMI) between 17.5 and 30.5 kg/m2, and a total body weight greater\n             than 50kg (110 lbs)\n\n        Exclusion Criteria:\n\n          1. Any condition which could possibly affect drug absorption.\n\n          2. Pregnancy or actively nursing females, or females of childbearing potential.\n\n          3. A positive urine drug screen."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01802476", 
            "org_study_id": "A5481015", 
            "secondary_id": "QBR115052"
        }, 
        "intervention": [
            {
                "arm_group_label": "Fixed Sequence Crossover Arm", 
                "description": "Treatment A consists of a single 125 mg oral dose of PD-0332991.", 
                "intervention_name": "Oral Drug Formulation of PD-0332991", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Fixed Sequence Crossover Arm", 
                "description": "Treatment B consists of a 1000 mL intravenous infusion of 50 mg of PD-0332991 administered over 4 hours at a constant rate.", 
                "intervention_name": "Intravenous Formulation of PD-0332991", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "PD-0332991", 
            "Absolute Bioavailability Study"
        ], 
        "lastchanged_date": "December 16, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5481015&StudyName=A%20Study%20Comparing%20the%20Plasma%20Drug%20Exposure%20of%20an%20Oral%20Dose%20of%20Palbociclib%20%28PD-0332991%29%20to%20an%20Intravenous%20Dose%20of%20Palbociclib%20%28PD"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "NOttingham", 
                    "country": "United Kingdom", 
                    "state": "Nottinghamshire", 
                    "zip": "NG11 6JS"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Single Dose, Fixed Sequence, 2-Period Cross-Over Absolute Oral Bioavailability Study In Healthy Volunteers Comparing Oral To Intravenous Administration Of PD-0332991", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Dose-Normalized AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8) divided by the administered dose. It is obtained from AUC (0 - t) plus AUC (t - 8).", 
                "measure": "Dose-Normalized Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]", 
                "safety_issue": "No", 
                "time_frame": "0 to 144 hours"
            }, 
            {
                "description": "AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).", 
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]", 
                "safety_issue": "No", 
                "time_frame": "0 to 144 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01802476"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "0 to 144 hours"
            }, 
            {
                "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) divided by the administered dose.", 
                "measure": "Dose-Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "0 to 144 hours"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "0 to 144 hours"
            }, 
            {
                "description": "The maximum observed plasma concentration divided by the administered dose.", 
                "measure": "Dose-Normalized Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "0 to 144 hours"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "0 to 144 hours"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                "measure": "Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "0 to 144 hours"
            }, 
            {
                "description": "CL is a quantitative measure of the rate at which a drug substance is removed from the body following an intravenous dose.", 
                "measure": "Systemic Clearance (CL)", 
                "safety_issue": "No", 
                "time_frame": "0 to 144 hours"
            }, 
            {
                "description": "Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.  Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling.  Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.", 
                "measure": "Apparent Oral Clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "0 to 144 hours"
            }, 
            {
                "measure": "Apparent Volume of Distribution after an Oral Dose (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "0 to 144 hours"
            }, 
            {
                "measure": "Volume of Distribution at Steady State after an IV Infusion (Vss)", 
                "safety_issue": "No", 
                "time_frame": "0 to 144 hours"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}